Search Results
Sole Dealer Manager to TriSalus Life Sciences, Inc.
Oppenheimer & Co. Inc. acted as Sole Dealer Manager to TriSalus Life Sciences, Inc. on its public warrant exchange of 7.0 million warrants
Sole Bookrunner on Vaxart's Registered Direct Offering
Oppenheimer & Co. Inc. acted as Sole Bookrunner on Vaxart’s $40MM Registered Direct Offering
Sole Bookrunner for WisdomTree
Oppenheimer & Co. Inc. acted as Sole Bookrunner for WisdomTree, Inc. (NYSE:WT) on its $345,000,000 Convertible Senior Notes Offering
Sole Bookrunner for Capital Southwest Corporation
Oppenheimer & Co. Inc. acted as Sole Bookrunner for Capital Southwest Corporation (NASDAQ: CSWC) on its $230,000,000 Convertible Notes Offering
Reflecting on Our Two-Day Strategy Session in Financial Institutions Group
In December 2023, the Financial Institutions Group held its annual strategic planning session, a two-day event challenging our bankers to collectively reflect on the year’s successes and challenges while charting a course for 2024 and beyond.
Q3 Private Placement Activity and M&A and Strategic Collaborations
Oppenheimer's Q3 update on VC, M&A, and BD&L activity for the biopharma sector.
Private Placement Activity and M&A and Strategic Collaborations
We are happy to share Oppenheimer's Quarterly Private Placement Insights as well as our M&A and Strategic Collaborations Insights. Spoiler Alert: The positive momentum of 2023 has carried over into 2024.
Placement Agent on Skye Bioscience's $50MM Private Placement Financing
Oppenheimer &. Co. Inc. acted as Placement Agent on Skye Bioscience’s $50MM Private Placement Financing
Placement Agent on Skye Bioscience's $40MM Private Placement
Oppenheimer &. Co. Inc. acted as Placement Agent on Skye Bioscience’s $40MM Private Placement
Placement Agent on Q32 Bio's Private Placement Financing
Oppenheimer &. Co. Inc. acted as Placement Agent on Q32 Bio’s $42MM Private Placement Financing